Overview

A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Bevacizumab
Paclitaxel